Molecular Determinants of μ-Conotoxin KIIIA Interaction with the Human Voltage-Gated Sodium Channel NaᵥV1.7

Ian H. Kimball[1,*], Phuong T. Nguyen[1,*], Baldomero M. Olivera[3],

Jon T. Sack[1,2,‡], Vladimir Yarov-Yarovoy[1,2,‡]

[1]Department of Physiology and Membrane Biology, UC Davis, Davis, CA, USA,

[2]Department of Anesthesiology and Pain Medicine, UC Davis, Davis, CA, USA,

[3]Department of Biology, University of Utah, Salt Lake City, UT, USA

* - these authors contributed equally to this work

‡ corresponding authors

Abstract

The voltage-gated sodium (Nav) channel subtype Nav1.7 plays a critical role in pain signaling, making it an important drug target. Here we studied the molecular interactions between μ-conotoxin KIIIA (KIIIA) and the human Nav1.7 channel (hNav1.7). We developed a structural model of hNav1.7 using Rosetta computational modeling and performed in silico docking of KIIIA using RosettaDock to predict residues forming specific pairwise contacts between KIIIA and hNav1.7. We experimentally validated these contacts using mutant cycle analysis. Comparison between our KIIIA-hNav1.7 model and the cryo-EM structure of KIIIA-hNav1.2 revealed key similarities and differences between Nav channel subtypes with potential implications for the molecular mechanism of toxin block. The accuracy of our integrative approach, combining structural data with computational modeling, experimental validation, and molecular dynamics simulations, suggests that Rosetta structural predictions will be useful for rational design of novel biologics targeting specific Nav channels.

Introduction

Voltage-gated sodium (Nav) channels play a key role in the action potential generation in excitable cells (Hille, 2001;Catterall, 2014;Ahern et al., 2016). The nine subtypes of Nav channel α-subunits (named Nav1.1-Nav1.9) are differentially expressed throughout tissues, and are targets of therapeutics for pain, cardiac arrhythmias, and epilepsy (Catterall et al., 2005). Human Nav1.7 (hNav1.7) channel is important for pain signaling and its mutations have been linked to severe pain disorders ranging from complete lack of pain sensation to extreme sensitivity to pain (Dib-Hajj et al., 2013;Bennett et al., 2019;Dib-Hajj and Waxman, 2019). Clinical use of local anesthetic drugs, such as lidocaine, is limited because they bind to a highly conserved receptor site within the Nav channel pore lumen, and are consequently non-selective among human Nav subtypes (Ragsdale et al., 1994;Yarov-Yarovoy et al., 2001;Yarov-Yarovoy et al., 2002;Nguyen et al., 2019). The receptor sites of other Nav blockers have nuanced differences between subtypes and molecular mechanisms of channel blockade that could enable rational design of Nav subtype-selective therapeutics (Payandeh and Hackos, 2018).

The search for novel Nav channel modulators has identified small disulfide-knotted peptide toxins from cone snails (conotoxins) (Wilson et al., 2011), which target the extracellular vestibule of the Nav channel pore and offer useful peptide scaffolds for rational design of novel peptide-based therapeutics to potentially treat pain, arrhythmias, and epilepsy (French et al., 2010;Gilchrist et al., 2014). μ-conotoxin KIIIA (KIIIA) is a 16 amino acid peptide that potently inhibits TTX-sensitive Nav channels (Zhang et al., 2007;Wilson et al., 2011;Khoo et al., 2012) (Figure 1A). A pain assay in mice suggested that KIIIA potentially has analgesic properties (Zhang et al., 2007). Notably, a variant of saxitoxin that targets the same receptor site in hNav1.7 as KIIIA is now in a Phase I clinical trial for treatment of post-operative pain (Mulcahy et al., 2019;Pajouhesh et al.,

2020;SiteOne Therapeutics, 2021). KIIIA has variable degrees of affinity and block for the

different Na_V channel subtypes, with 5 nM affinity for rat $Na_V1.2$, 37 nM for rat $Na_V1.4$, and 97

nM for $hNa_V1.7$ (Zhang et al., 2007;McArthur et al., 2011;Wilson et al., 2011). Structure-activity

relationship studies have identified the KIIIA residues K7, W8, R10, D11, H12 and R14 as key for

binding to various Na_V channel subtypes (Zhang et al., 2007;McArthur et al., 2011). Specifically,

K7, R10 and R14 have been shown to contribute to both binding affinity and block of $hNa_V1.7$

(McArthur et al., 2011). Notably, the relative contribution of KIIIA residues in binding to Na_V

channels vary between channel subtypes. For example, substitution R14A in KIIIA reduces the

affinity for $Na_V1.2$ and $Na_V1.4$ by 740-fold and 180-fold, respectively, while reducing the affinity

for $Na_V1.7$ by only 5-fold (McArthur et al., 2011). Similarly, substitution R10A in KIIIA reduces

the affinity for $Na_V1.2$ and $Na_V1.4$ by 32-fold and 27-fold, respectively, while reducing the affinity

for $Na_V1.7$ by only 14-fold (McArthur et al., 2011). In addition, KIIIA blocks Na_V channels

incompletely and can co-bind with tetrodotoxin (TTX) to TTX-sensitive Na_V channels (Zhang et

al., 2009).

A previous study identified the importance of Na_V channel residues near the selectivity filter on

the P2-helix in domain III (DIII) for their apparent coupling to residues R10 and R14 on KIIIA

(McArthur et al., 2011). Notably, the P2-helix in DIII of $hNa_V1.7$ has threonine at position 1398

and an isoleucine at position 1399, while all other human Na_V channels have methionine and

aspartate at the corresponding positions (McArthur et al., 2011). These residues were proposed to

play an important role in the selectivity of KIIIA binding to $Na_V1.2$ and $Na_V1.4$ versus to $Na_V1.7$

(McArthur et al., 2011). Molecular modeling of KIIIA binding to $rNa_V1.4$ using restraints from

experimental data suggested specific contacts between KIIIA and the P2-helix in DIII (Korkosh et

al., 2014). However, these studies did not provide an explanation for the significant effect of the

KIIIA mutations H12A, W8A and D11A on toxin affinity.

In this study, we used computational and experimental approaches to investigate the molecular

mechanism of the KIIIA interaction with hNav1.7. We specifically focused on human Nav1.7 as

a target due to its importance in pain signaling and our goal to rationally design novel KIIIA-based

peptides targeting human Nav1.7 as potential therapeutics to treat chronic pain. We selected KIIIA

among conotoxins identified to date because it has the highest potency for human Nav1.7 (Zhang

et al., 2007;McArthur et al., 2011). We present a structural model of KIIIA binding to the hNav1.7

channel based on the eukaryotic electric eel Nav1.4 cryo-EM structure (Yan et al., 2017). Our

model revealed binding of KIIIA to hNav1.7 at the interface between the P2-helices in domain II

(DII) and DIII, which exposed a partially open ion conduction pathway that may explain the

incomplete blocking characteristic of the toxin. While many KIIIA mutations have been previously

characterized on Nav1.2 and Nav1.4 channels, only a limited number of KIIIA mutants had been

tested on Nav1.7. We independently characterized many of the KIIIA mutations on Nav1.7 in our

laboratory, to confirm previously published data and to validate affinities that serve as the basis of

mutant cycle calculations. Our study for the first time tested effects of the following mutations:

(1) KIIIA W8 and D11A on the wild-type hNav1.7; (2) hNav1.7 Y362C, E919Q, D923A with the

wild-type KIIIA; (3) paired toxin—channel mutations K7A—E919Q, D11A—E919Q, and

H12A—D923A. We identified several unique contacts between KIIIA and extracellular loops on

hNav1.7, providing key structural insights into binding specificity for different Nav channel

subtypes. We used mutant cycle analysis to validate representative pairwise contacts between

specific residues on KIIIA and hNav1.7 identified from our structural model of the KIIIA –

hNav1.7 complex. Remarkably, the published cryo-EM structure of KIIIA - hNav1.2 complex (Pan

et al., 2019) agrees with findings from our computational modeling and functional study. The

accuracy of peptide toxin – Na$_V$ channel interaction modeling suggests that Rosetta predictions are

sufficiently precise for the rational design of novel selective peptide inhibitors targeting Na$_V$

channels with high selectivity and potency.

Results

Molecular modeling suggests eccentric binding of KIIIA to DII and DIII of the hNa$_V$1.7 pore

To characterize the molecular mechanism of the KIIIA interaction with hNa$_V$1.7, we utilized

computational modeling and functional testing approaches as described below. When this study

was conducted, the cryo-EM structure of the electric eel Na$_V$1.4 (eeNa$_V$1.4) (Yan et al., 2017)

channel was the closest structural homolog available to build a homology model of hNa$_V$1.7. The

eeNa$_V$1.4 structure shares ~54% sequence identity with hNa$_V$1.7 overall and ~75% sequence

identity over the hNa$_V$1.7 pore region. We used the RosettaCM modeling approach (Song et al.,

2013;Bender et al., 2016) to generate a structural model of hNa$_V$1.7 based on the eeNa$_V$1.4

structure (Yan et al., 2017) and the Rosetta protein-protein docking approach (Gray et al.,

2003;Wang et al., 2007;Bender et al., 2016) to predict a structure of the KIIIA – hNa$_V$1.7 complex

and identify specific residues forming interactions between KIIIA and hNa$_V$1.7 (see Materials and

methods, and coordinates of our KIIIA – hNa$_V$1.7 model in Supplement File – Model 1). Our

model revealed an eccentric or off-center binding of KIIIA to hNa$_V$1.7, where the KIIIA helical

region is positioned off the central axis of the selectivity filter with the positively charged KIIIA

residues facing the P2-helices (Figure 1B). The position and orientation of KIIIA in our model is

different from KIIIA binding to the P2-helix in DIII previously suggested by computational

modeling (McArthur et al., 2011;Korkosh et al., 2014) and lanthanide-based resonance energy

transfer (Kubota et al., 2017) studies. The KIIIA binding site just above the selectivity filter in our

model is different from TTX and saxitoxin (STX) binding deeper into the selectivity filter region

(Shen et al., 2018;Shen et al., 2019). Mapping of the open aqueous space surrounding the KIIIA -

hNav1.7 binding interface revealed a tunnel traversing from the extracellular environment to the

channel pore cavity (Figure 1C). The most constricted part of this aqueous tunnel is within the

selectivity filter region, where the radius of the open aqueous space narrows to ~1 Å. KIIIA bound

to the upper region of the selectivity filter and constricted the open space to a minimum radius of

~2.5 Å, which is large enough to allow sodium ion conduction and consistent with the

characteristic incomplete block of Nav channels by KIIIA (Zhang et al., 2007;McArthur et al.,

2011). Notably, the cryoEM structure of KIIIA – hNav1.2 (Pan et al., 2019) reveals a binding pose

similar to our model, as described later in this paper (Figure 4A).

Pairwise interactions identified from the KIIIA - h Nav**1.7 complex model**

To identify key KIIIA residues at the toxin – channel interface, we first examined the contribution

of KIIIA residues to the interaction with hNav1.7 using an *in silico* alanine scan. Non-cysteine

residues on KIIIA were mutated to alanine and changes in Rosetta binding energy (ΔΔG) were

reported in the arbitrary Rosetta Energy Units (R.E.U). Our analysis revealed the active surface of

KIIIA with residues K7, W8, R10, H12, and R14 each having significant contribution to the

binding energy (Figure 1D and E). K7, W8, R10, and H12 are located on the same face of KIIIA's

alpha helix, while R14 is located within the C-terminal tail region of the toxin. Our KIIIA –

hNav1.7 model predicts that positively charged residue K7 forms a salt bridge with E919 on the

P2-helix in DII (we use hNav1.7 residue numbering throughout the manuscript unless otherwise

noted) (Figure 1F). In addition, W8 and H12 were shown to form hydrogen bonds with Y339 on

the extracellular loop between S5 and the P1-helix (S5P1) in DI and D923 on the P2-helix in DII,

respectively (Figure 1F). D11 is positioned near the interface between the P2-helices in DII and

DIII and forms hydrogen bonds with both K7 on KIIIA and T1398 on the P2-helix in DIII (Figure

1F). The other positively charged KIIIA residues, R10 and R14, interact with two negatively

charged residues: D1662 on the extracellular loop S5P1 in DIV and E1417 on the extracellular

loop between the P2-helix and S6 (P2S6) in DIII. Notably, R14 also interacts with Y1416 on the

extracellular P2S6 loop in DIII and contributes to a cation-π interaction tower formed by Y1402

on the P2-helix in DIII, R896 on the extracellular loop S5P1 in DII, and Y1416 (Figure 1F). The

R10 of KIIIA is in proximity to I1399 on the P2-helix in DIII in agreement with the significant

coupling energy between R10 and D1241 on the P2-helix in DIII in rNav1.4 reported previously

(McArthur et al., 2011). While KIIIA N3 is near E307 in the extracellular loop S5P1 in DI, this

interaction may not be substantial as shown by minimal change in Rosetta binding energy ($\Delta\Delta G$)

from our *in silico* alanine scan (Figure 1D). N3 has been shown to be not critical for KIIIA

interaction with rNav1.2 and rNav1.4 channels (Zhang et al., 2007).

Functional mapping of KIIIA residues at the toxin – channel interface supports the predicted

KIIIA – hNav1.7 model

To test the accuracy of our KIIIA – hNav1.7 model, we first confirmed the activity of the wild-

type KIIIA on the wild-type hNav1.7 using whole-cell voltage-clamp recordings. To estimate the

KIIIA binding affinity, we performed concentration-response experiments and obtained an IC_{50} of

410±160 nM when fit to a Hill equation assuming a single binding site (Figure 2). This fitting

suggested a maximal block of 95±3.3% of total current in agreement with previous studies

concluding that Nav channels retain 5-10% of their conductance when blocked by KIIIA (Zhang

et al., 2007;McArthur et al., 2011). The WT-KIIIA first order association rate (k_{on}) was determined

based on single exponential fits to the kinetics of block after toxin addition (Table 1, see Materials

and Methods equation 3). The extremely slow dissociation of the wild-type KIIIA from hNav1.7

complicated accurate determination of dissociation kinetics, as less than 10% recovery was

observed during wash-off experiments lasting up to ~30 min. Constraining single exponential fits

of the dissociation data to assume current recovers to initial levels, we obtained k_{off} of 0.003 min^{-1}

and a K_d of 59 nM, which is close to the previously reported K_d of 97 nM (McArthur et al., 2011).

Temperature differences between our experiments (~21°C) and the prior study (~25°C) might be

responsible for differences in kinetics and affinities.

We performed an alanine scan of KIIIA residues that are positioned at the interface with hNav1.7

in our model to determine their effect on binding affinity to the wild-type channel. As with WT-

KIIIA, k_{on}, k_{off}, and K_d were determined from single exponential fits of peak current during

depolarizing voltage steps and are summarized in Table 1; representative data are shown in Figure

2—figure supplement 1A. In the absence of Hill fits of concentration response curves for KIIIA

variants, k_{on} was calculated according to equation 2 (see Materials and Methods). KIIIA

substitutions K7A and H12A both had nearly 100-fold decreases in affinity for the wild-type

hNav1.7 channel, in agreement with previously published data (Zhang et al., 2007;Zhang et al.,

2009;McArthur et al., 2011). We found that KIIIA substitutions W8A and D11A had a 50- and

10-fold reduction in affinity for the wild-type hNav1.7 channel, respectively (Figure 2D). The

KIIIA point mutations had little effect on the association rate relative to wild-type KIIIA, with

D11A showing the largest effect at a 3-fold increase in association rate (Figure 2D). The observed

change in affinity from neutralizing mutations of charged residues was largely driven by 36-fold

to 116-fold increases in toxin dissociation rates (Figure 2D). The KIIIA-D11A substitution resulted

in both an increase in k_{on} and k_{off}. This substitution also would eliminate contact with Nav1.7-

specific T1398 on the P2-helix in DIII observed in our model. Prior studies had observed that the

D11A substitution had no effect on dissociation from rNav1.2, but had a small effect on rNav1.4

binding—slowing k_{off} 4-fold and very little effect on k_{on} (Zhang et al., 2007). The reductions in

KIIIA affinity from alanine mutations seen *in vitro* correspond to key residues forming the KIIIA-

hNav1.7 interface observed in our model (Figure 1B).

We estimated maximal block from fractional current remaining at sub-saturating concentrations

of toxin variants by assuming a single binding site with $K_d = k_{off} / k_{on}$ and extrapolating to maximal

block (see Materials and Methods equations 2, 5, and 7). We caution that these estimates of

maximal block are model-dependent and of limited precision, and not as definitive as single

channel measurements or experiments in saturating doses of toxin would be. Bearing these

cautions in mind, we note that alanine substitution at position 7 (Figure 2C, Table 1) reduces

maximal block to 74±4.9%, while substitutions at positions 8 and 11 did not detectably reduce

maximal block (90±9.4%, and 100±1.2%, respectively) (Table 1). In addition to levels of block

previously reported for K7A, H12A, R10A, R14A variants (McArthur et al., 2011), these results

are consistent with an orientation placing K7 towards the acidic residues of the selectivity filter

(Figure 1F).

Table 1

Block of hNav1.7 by KIII variants

Fractional block at saturating concentrations determined from extrapolation from kinetic data.

Channel and Toxin (n)	k_{on} ($\mu M^{-1}min^{-1}$)	SEM	k_{off} (min^{-1})	SEM	K_d (μM)	SEM	F_{block}	SEM
*WT-h*Na$_V$*1.7 x WT-KIIIA (5)*	0.054	0.011	0.003	0.001	0.059	0.007	0.95[a]	0.033
*WT-h*Na$_V$*1.7 x KIIIA-K7A (5)*	0.064	0.018	0.274	0.012	4.291	1.507	0.74	0.049
*WT-h*Na$_V$*1.7 x KIIIA-W8A (3)*	0.110	0.045	0.329	0.097	2.990	1.719	0.90	0.094
*WT-h*Na$_V$*1.7 x KIIIA-D11A (4)*	0.164	0.014	0.109	0.008	0.663	0.056	1.00	0.012
*WT-h*Na$_V$*1.7 x KIIIA-H12A (5)*	0.047	0.027	0.349	0.240	7.405	2.801	*0.88[b]*	*0.019*

a – Fractional block was determined from the Hill fit of concentration-response data (Figure 2B).

b – Fractional block reported by McArthur, et al., 2011. This value was used to constrain kinetic parameter estimates

from association experiments.

n – number of cells tested.

Functional mapping of hNa$_V$1.7 residues at the toxin – channel interface support KIIIA

binding to the P2-helices in DI and DII

To test the accuracy of the orientation of KIIIA in our model, we used mutations in the P2-helices

of DI and DII in the outer pore (Figure 1). We mutated the hNa$_V$1.7 N365 and Y362 residues on

the P2-helix in DI and E919 and D923 on the P2-helix in DII (Figure 1F). N365A slowed

dissociation such that k_{off} was not measurable during the course of our wash-out experiments,

precluding measurement of affinity, but suggesting a limited contribution to toxin binding of this

position (Figure 2–Supplement 1, Table 2). Y362C however, produced a modest increase in both

association and dissociation yielding a 7.5-fold reduction in affinity corresponding to 1.2

kcal•mol^{-1} (Figure 2E). The E919A mutation did not produce measurable current, yet the E919Q

mutation produced functional currents and reduced binding of the wild-type KIIIA by 42-fold

corresponding to a 2.2 kcal•mol^{-1} reduction in affinity (Figure 2E). Our model shows a salt bridge

between E919 and toxin residue K7 (Figure 1F); the effect of this charge neutralization

demonstrates the importance of an acidic residue at this position for toxin binding. The lack of

current in the E919A mutant points to a potential steric contribution of this location for pore

stability given the proximity to the selectivity filter (Figure 1C, 1F), or poor expression. Our model

also shows a hydrogen bond between toxin residue H12 and D923, one helix turn up the DII-P2

helix from E919 (Figure 1F). The substitution D923A likewise reduced affinity of the wild-type

KIIIA by 40-fold, or 2.2 kcal•mol^{-1} (Figure 2E) suggesting the elimination of such an interaction.

Overall, hNav1.7 mutations Y362C, E919Q, and D923A reduced the binding of the wild-type

KIIIA to hNav1.7 in agreement with our structural model of the KIIIA – hNav1.7 complex and

published KIIIA – hNav1.2 structure (Pan et al., 2019). The effects of mutations E919Q and

D923A in the P2-helix in DII are consistent with the toxin – channel protein-protein interface

suggested by our model (see representative data in Figure 2—figure supplement 1B). Overall, our

KIIIA alanine scan experiments support the toxin – channel protein-protein interface observed in

our KIIIA – hNav1.7 model and the published KIIIA - Nav1.2 structure (Pan et al., 2019).

Table 2

Block of hNav1.7 mutants by KIIIA

Fractional block at saturating concentrations determined from kinetic data.

Channel and Toxin (n)	k_{on} ($\mu M^{-1}min^{-1}$)	SEM	k_{off} (min^{-1})	SEM	K_d (μM)	SEM	F_{block}	SEM
WT-hNav1.7 x WT-KIIIA (5)	0.054	0.011	0.003	0.001	0.059	0.007	0.95[a]	0.033
Y362C x WT-KIIIA (3)	0.101	0.016	0.044	0.004	0.436	0.052	0.75	0.055

N356A x WT-KIIIA (2)	0.102	0.010	n.d.[b]	-	n.d.	-	0.80	0.004
E919Q x WT-KIIIA (3)	0.040	0.003	0.101	0.003	2.51	0.16	0.92	0.028
D923A x WT-KIIIA (3)	0.083	0.022	0.193	0.022	2.34	0.41	0.89	0.037

a – Fractional block was determined from the Hill fit of concentration-response data (Figure 2B)

b – No dissociation was observed during washout, F_{Block} is observed block.

n – number of cells tested.

Double Mutant Cycle Analysis confirms pairwise interactions between KIIIA and hNa$_V$1.7-

DII

Our alanine scan and previous studies have demonstrated the importance of several toxin and

channel residues for the binding of KIIIA to hNav1.7. To further validate specific pairwise toxin

– channel contacts predicted by our KIIIA – hNav1.7 model, we performed double-mutant cycle

analysis experiments (Hidalgo and MacKinnon, 1995;Schreiber and Fersht, 1995;Ranganathan et

al., 1996) assessing the coupling between two channel-toxin residue pairs observed in our model,

and one pair that was not observed to interact. Specifically, we compared the effects on toxin

affinity of hNav1.7 single point mutations and KIIIA single substitution variants at positions

corresponding to predicted contact residues, and "double-mutants" consisting of both channel

mutations and toxin substitutions (Figure 3A and Figure 3—figure supplement 1). Pairwise

contacts can be identified from such experiments on the basis of the path-independence from the

wild-type condition to the double-mutant condition: the reduction in binding affinity resulting from

a mutation to either side of an interacting pair should be non-additive in the double-mutant

condition (Hidalgo and MacKinnon, 1995;Ranganathan et al., 1996). Residue pairs that exhibit

additive effects of the double-mutant relative to the single mutants do not make functional

interactions contributing to binding. These effects are quantified by calculating the coupling

coefficient Ω (Materials and Methods Equation 8). Coupling coefficients differing from 1 indicate

higher degrees of coupling and are expected with close-contact interactions between the native

sidechains (Hidalgo and MacKinnon, 1995;Schreiber and Fersht, 1995;Ranganathan et al., 1996).

Importantly, while directly interacting pairs are expected to show coupling, coupling can also

result from allosteric effects. We tested the following pairs of double mutants: Nav1.7-E919Q x

KIIIA-K7A, D923A x H12A (Figure 3—figure supplement 1), which both interact directly in our

model (Figure 4A), and E919Q x D11A, which do not interact directly in our model, with the

hypothesis that only the interacting pairs will exhibit coupling coefficients divergent from 1.

E919Q x D11A reduced the toxin affinity 240-fold compared to wild-type channel and toxin (K_d

=14.2±5.8 μM), and 6- and 21-fold relative to the single mutations, E919Q and D11A (2.51±0.16

μM and 0.66±0.06 μM, respectively) (Figure 3A and Table 3). The large discrepancy between the

relative reductions in affinity of the double-mutant compared to wild-type or the single mutants

corresponded to a coupling coefficient near 1 (Ω = 0.50±0.38), suggesting little functional

interaction between E919 and D11, consistent with the separation of these residues in our model

(Figure 3D and Table 4) (Schreiber and Fersht, 1995;Ranganathan et al., 1996). In contrast, the

degree to which affinity was weakened by mutations E919Q and K7A together (2.47±1.32 μM)

was similar to E919Q (2.51±0.16 μM) or K7A alone (4.29±1.51 μM) (Figure 3A and Table 3),

suggesting interaction between E919Q and K7A that is eliminated upon mutation of either side (Ω

= 0.014±0.012) (Figure 3D and Table 4). Likewise, the degree to which affinity was weakened by

mutations D923A and H12A together (2.40±1.45 μM) was similar to D923A (2.34±0.41 μM) or

H12A alone (7.41±4.6 μM) (Figure 3A and Table 3). The non-additive effect of these substitutions

suggests close contact between D923 and H12 is eliminated upon mutation of either side (Ω =

0.0082±0.0091) (Figure 3D and Table 4). The coupling observed between these pairs are

consistent with pairwise interactions between charged amino acids (Hidalgo and MacKinnon,

1995;Schreiber and Fersht, 1995;Ranganathan et al., 1996). These results are consistent with E919

– K7 and D923 – H12 pairwise interactions observed in both our model (Figure 4A) and the recent

structure of KIIIA - Nav1.2 complex (Pan et al., 2019), which both show strong electrostatic

interactions between these residue pairs, providing further experimental validation of the KIIIA

binding pose observed in our model.

Table 3

Block of double-mutant cycle pairs of hNaᵥ1.7 and KIIIA

Channel and Toxin (n)	k_{on} ($\mu M^{-1}min^{-1}$)	SEM	k_{off} (min^{-1})	SEM	K_d (μM)	SEM	F_{block}	SEM
WT-hNaᵥ1.7 x WT-KIIIA (5)	0.054	0.011	0.003	0.001	0.059	0.007	*0.95[a]*	0.033
WT-hNaᵥ1.7 x KIIIA-K7A (5)	0.064	0.018	0.274	0.012	4.29	1.51	0.74	0.049
WT-hNaᵥ1.7 x KIIIA-D11A (4)	0.164	0.014	0.109	0.008	0.66	0.056	1.00	0.012
WT-hNaᵥ1.7 x KIIIA-H12A (5)	0.047	0.027	0.349	0.240	7.40	2.80	*0.88[b]*	*0.019*
E919Q x WT-KIIIA (3)	0.040	0.003	0.101	0.003	2.51	0.16	0.92	0.028
E919Q x KIIIA-K7A (3)	0.044	0.015	0.108	0.021	2.47	1.32	0.48	0.066
E919Q x KIIIA-D11A (3)	0.124	0.046	1.790	0.369	14.2	5.79	*0.92[c]*	*0.028*
D923A x WT-KIIIA (3)	0.083	0.022	0.193	0.022	2.34	0.41	0.89	0.037
D923A x KIIIA-H12A (2)	0.183	0.065	0.440	0.098	2.40	1.45	0.49	0.092

a – Fractional block was determined from the Hill fit of concentration-response data (Figure 2B).

b – Fractional block reported by McArthur, et al., 2011 was used to constrain kinetic parameter estimates from

association experiments.

c – Fractional block from E919Q mutation assumed to be the same as WT-KIIIA given lack of effect by KIIIA-D11A.

n – number of cells tested.

Table 4

Coupling coefficients from double-mutant cycle experiments

	D923A x H12A	error	E919Q x K7A	error	E919Q x D11A	error
Ω	0.0082	0.0091	0.014	0.012	0.50	0.38

Error calculated by linear propagation of uncertainty (Ku, 1966;Hidalgo and MacKinnon, 1995).

Nav channel isoforms with distinct toxin affinities have divergent residues at the KIIIA

binding interface

The differences in KIIIA binding affinity between the Nav channel isoforms likely arise from

variations in sequence in the P2 helices and extracellular loop regions (Figure 4A and B). The

published structure of the KIIIA - hNav1.2 complex (Pan et al., 2019) was not available when we

generated our structural model of the KIIIA - hNav1.7 complex, yet it is consistent with our

structural model and further supports this observation. The backbone root mean square deviation

(RMSD) of the KIIIA - hNav1.7 model and the KIIIA - hNav1.2 structure over KIIIA and the P2-

helices is ~1.0 Å (Figure 1—figure supplement 1B). The specific pairwise contacts between K7-

E919 and H12-D923 in our KIIIA - hNav1.7 model, validated by our mutant cycle analysis, are in

agreement with the corresponding pairwise contacts between K7-E945 and H12-D949 observed

in the KIIIA - hNav1.2 complex structure (Figure 4A and B) (Pan et al., 2019). Our KIIIA -

hNav1.7 model also predicted other contacts observed in the published KIIIA - hNav1.2 structure

(Pan et al., 2019), including pairwise interactions between KIIIA N3 and W8 with E307 and Y339,

respectively, on the extracellular S5-P1 loop in DI (Figure 4A and B).

The KIIIA critical residues D11 and R10 in our KIIIA - hNav1.7 model are positioned similarly

in the KIIIA - hNav1.2 structure, but details of toxin – channel interactions involving these residues

are different (Figure 4A). D11 forms a hydrogen bond with T1398 on the P2-helix in DIII in our

KIIIA - hNav1.7 model (Figure 4A), but the substitution of Thr (T1398) hNav1.7 to Met (M1425)

on the P2-helix in DIII in hNav1.2 removes this interaction, and a new hydrogen bond is formed

between D11 with the nearby residue Y1429 (Figure 4—figure supplement 1) (Pan et al., 2019).

In the hNav1.2 structure, R10 interacts with D1426 on the P2-helix in DII, but the corresponding

position in hNav1.7 is I1399, eliminating possible charge interaction with this residue in hNav1.7

(Figure 4A and B). This difference potentially contributes to the R10 interaction with the nearby

acidic residue D1662 on the extracellular S5-P1 loop in DIV of hNav1.7 (Figure 4—figure

supplement 1). It is noticeable that Asp at position 1662 is unique to hNav1.7 - corresponding

residues at this position in other Nav channel subtypes are Val, Ala, and Ser (Figure 4B).

Additionally, the corresponding residues to T1398 and I1399 on the P2-helix in DIII of hNav1.7

are Met and Asp, respectively, in all other human Nav channels. Because of that, it seems

reasonable to hypothesize that these residues provide a major contribution to structural determinant

of KIIIA interaction with hNav1.7.

The R14 residue on KIIIA is important for KIIIA binding to Nav channels and the substitution of

Arginine to Alanine at this position has been shown to gain selectivity for hNav1.7 versus hNav1.2

(McArthur et al., 2011). Both our KIIIA - hNav1.7 model and the KIIIA - hNav1.2 structure show

the positively charged R14 forming cation – π interactions with Y1416 (hNav1.7) or Y1443

(hNav1.2) on the extracellular P2-S6 loop in DIII (Figure 4A). Notably, in the KIIIA - hNav1.2

structure R14 is also in proximity to the negatively charged E919 (hNav1.2 numbering) on the

extracellular S5-P1 loop in DII (Pan et al., 2019). However, in our KIIIA - hNav1.7 model, R14

is in proximity to T893 on the extracellular S5-P1 loop in DII (which is corresponding to E919 in

hNav1.2) and E1417 on the extracellular P2-S6 loop in DIII (Figure 4A and B). We reason that

these differences may contribute to the reported selectivity of KIIIA R14A substitution against

hNav1.7.

Overall, despite the similarity in binding pose and channel architecture, sequence variance at KIIIA

binding site, comprised of the P2 helices and extracellular loop regions likely contribute to

differences in KIIIA binding affinity of between hNav1.7 and hNav1.2, and perhaps also among

other channel isoforms.

Structural dynamics of KIIIA binding to hNav1.7 and hNav1.2 revealed by molecular

dynamics simulations

To further study the molecular mechanism of the KIIIA interaction with hNav1.7, we performed

molecular dynamics (MD) simulations of our KIIIA - hNav1.7 complex model. The 3 independent

1.5 μs MD simulations revealed highly dynamic KIIIA binding with the backbone RMSDs

between KIIIA and hNav1.7 interface fluctuating between 3.5 – 4.5 Å (Figure 5 – figure

supplement 1). Remarkably, we observed key positively charged residues K7 and R10 on KIIIA

interacted not only with the acidic residue on the P2-helix in DII identified from our model (E919

and D923) but also with acidic residues on the P2-helix in DIV. The density projection of these

residues on the membrane plane revealed the primary amine group of K7 was mostly localized

near D923 and E919 on P2-helix in DII and D1690 on P2-helix in DIV (see sites A1, A2 and A3

in Figure 5A) while R10 was localized near E919 (DII) and D1690 (DIV) (Figure 5 – figure

supplement 2). The dynamic interactions of K7 with multiple acidic residues on P2 helices is

consistent with our functional characterization of KIIIA - hNav1.7 interactions where we observed

a 100-fold reduction in K_d for the K7A mutation on KIIIA and only a 42-fold reduction for E919Q

mutation on the channel. As an indication of highly dynamic interactions of KIIIA with hNav1.7,

we also observed key residues on KIIIA formed interactions with multiple residues on the channel

as shown in the fractional contact map (Figure 5). Notably, W8 frequently formed contacts with

K310 and Y339 on the extracellular S5-P1 loop in DI. H12 interacted mainly with D923 on the

P2-helix in DII and also with the backbone of P895 on the extracellular S5-P1 loop in DII. D11 is

positioned deep at the interface between DII and DIII within a region formed by hNav1.7 residues

R911 on the P1-helix in DII, E919 on the P2-helix in DII, and Y1402 on the P2-helix in DIII. R14

primarily interacted with Y1416 on the extracellular P2-S6 loop in DIII, and T893, L894, P895

and R896 on the extracellular loop in DII and did not maintain interaction with E1417 on the

extracellular loop in DIII as initially identified in our model (Figure 5—figure supplement 2). In

addition, during equilibration we consistently observed the initial placed sodium ion in the

selectivity filter localized near E916 and E919 on the P1-P2-helix region in DII (Figure 5A – figure

supplement 1), which agrees with the density identified as a sodium ion at the same position in the

structure of the KIIIA - hNav1.2 complex (Pan et al., 2019). This sodium ion quickly diffused out

to the extracellular bulk via an open passage formed between KIIIA and the selectivity filter region

of the channel. The sodium ion escape is consistent with the incomplete block of Nav current

observed in experiments (Figure 2) and incomplete reduction of the unitary Nav channel

conductance when KIIIA is bound (Zhang et al., 2007;McArthur et al., 2011).

We used the cryoEM structure of KIIIA - hNav1.2 complex (Pan et al., 2019) to study structural

dynamics at the toxin – channel interface and compare them to dynamics observed in our KIIIA -

hNav1.7 complex model (Figure 5A). We conducted 3 independent 1 μs MD simulations using

the same procedure as applied for the KIIIA - hNav1.7 model (see Materials and Methods). Similar

to the simulations of our KIIIA – hNav1.7 model, the KIIIA - hNav1.2 complex structure was

dynamic during simulations with the RMSDs at the toxin – channel interface between 3 - 5 Å

(Figure 5 – supplement 1). We also observed that key positively charged residues K7 and R10 on

KIIIA interacted with multiple acidic residues on the P2 helices of DI, DII, and DIV on hNav1.2

(Figure 5B). The primary amine group of K7 was mainly localized near E945 and D949 on the P2-

helix in DII and D1426 on the P2-helix in DIII (see sites B1, B2 and B3 in Figure 5B). Interactions

with the conserved acidic residues D1717 on the P2-helix in DIV (corresponding to D923 and

D1690 in hNav1.7, respectively) were more limited compared to that in the simulations of KIIIA

- hNav1.7 model (see site A3 in Figure 5A). Similarly, R10 was localized near E945 on the P2-

helix in DII and D1426 on the P2-helix in DIII while interactions with the conserved acidic residue

D1717 (D1690 in hNav1.7) were less dominant compare to that in hNav1.7 (Figure 5 – figure

supplement 1). These differences between hNav1.2 and hNav1.7 can be explained by a

contribution of a single residue substitution in P2-helix in DIII. Particularly, D1426 on the P2-

helix in DIII of hNav1.2 is conserved among all human Nav channel isoforms, except for hNav1.7,

which has I1399 at this position (Figure 4). The absence of an acidic residue, Asp at the 1399

position in hNav1.7 (D1426 in hNav1.2), substituted by a hydrophobic residue, I1399 may

facilitate interactions of positively charged K7 and R10 with the nearby acidic residue D1690 on

the P2-helix in DIV in hNav1.7 (Figure 5—figure supplement 1). Indeed, functional studies

showed that the mutation R10A produced a 35% reduction in KIIIA block of rNav1.4, while the

loss of toxin block caused by the R10A mutation was largely rescued by hNav1.7-like Ile on the

P2-helix in DIII (McArthur et al., 2011). Based on these observations, we speculate that dynamic

interactions of basic residues K7 and R10 on KIIIA with acidic residues on P2-helix on hNav

channels, driven by sequence variability at toxin – channel interface may provide a structural basis

for differences in KIIIA interactions among hNav channel isoforms. The sodium ion in the KIIIA

- hNav1.2 structure at the site formed by E942 and E945 (corresponding to E916 and E919 in

hNav1.7) on the P1-P2-helix region in DII of hNav1.2 quickly diffused out to the extracellular

bulk, in agreement with an incomplete block by KIIIA (Zhang et al., 2007) and our simulation of

the KIIIA - hNav1.7 model (Figure 5A and B). We did not observe re-entering events of sodium

ions into the hNav1.2 selectivity filter, similarly to our simulations of the KIIIA - hNav1.7 model.

Discussion

Computational modeling and functional testing reveal molecular determinants of μ-conotoxin KIIIA interaction with Nav1.7

Our computational model of hNav1.7, docking of KIIIA to the hNav1.7 model, and functional

testing of KIIIA and hNav1.7 mutations presented here were completed prior to the publication of

KIIIA - hNav1.2 complex structure (Pan et al., 2019). While hNav1.7 and hNav1.2 channels share

sequence homology within most of the KIIIA binding region, they exhibit several key differences

at the toxin - channel interface. We functionally characterized specific pairwise contacts between

KIIIA and hNav1.7 predicted by our model, particularly between K7 on KIIIA and E919 on the

P2-helix in DII and also between H12 on KIIIA and D923 on the P2-helix in DII. These pairwise

interactions agree with the corresponding pairwise interactions between K7-E945 and H12-D949

observed in the KIIIA - hNav1.2 complex structure (Figure 4A and B) (32). Interestingly, we also

observed that our KIIIA – hNav1.7 complex model based on the eeNav1.4 structure is similar to

our earlier KIIIA – hNav1.7 complex model based on the bacterial NavAb channel structure using

experimental restraints (PDB: 3RVY (Payandeh et al., 2011)). In this effort, the pairwise distance

constraints from available experimental data were used to model the interactions of GIIIA toxin, a

close homolog of KIIIA with the homology model of hNav1.4 based on the bacterial NavAb

structure. The model GIIIA – hNav1.4 were then subsequently used to build the KIIIA – hNav1.7

model. It predicted accurately the KIIIA orientation and both the interaction of K7 with E919 and

H12 with D923 (Figure 1—figure supplement 1A). However, the NavAb based model failed to

identify the pairwise interaction of W8 and Y339 (interacted with E926 instead). This likely due

to the limitation of the bacterial template with the difference in pore architecture compared to

mammalian Nav channels and the absence of extracellular loop regions in the NavAb based model.

Together, our work has demonstrated the predictive power of structural modeling with different

degrees of experimental restraints to study peptide toxin – channel interactions.

The Cryo-EM structures of Nav1.1, Nav1.2, Nav1.3, Nav1.4, Nav1.5, Nav1.6, Nav1.7, and Nav1.8

channels (Pan et al., 2018;Pan et al., 2019;Shen et al., 2019;Jiang et al., 2020;Jiang et al., 2021;Pan

et al., 2021;Huang et al., 2022a;Huang et al., 2022b;Li et al., 2022;Fan et al., 2023) revealed that

the extracellular vestibule of the channel pore targeted by KIIIA is surrounded by several relatively

long loop regions, raising the possibility that the access pathway to the KIIIA binding site is

relatively narrow. Restricted access and escape pathways for KIIIA binding could confer the

relatively slow k_{on} and k_{off} rates observed in our functional studies (Figures 2 and 3) and previously

published data (Zhang et al., 2007;McArthur et al., 2011;Wilson et al., 2011). We speculate that

variability in the Nav channel extracellular vestibule loops could underlie the differences in KIIIA

kinetics.

While our KIIIA - hNav1.7 model and the published KIIIA - hNav1.2 structure are supported by

functional data, further interactions of key charged residues K7 and R10 on KIIIA with multiple

acidic residues on the channels was observed in our MD simulations and could provide insight

into selectivity of the toxin and channel block. Notably, the unique residue I1399 on the P2-helix

in DIII of hNav1.7 may contribute to KIIIA binding on hNav1.7 by influencing the interactions of

K7 and R10 on KIIIA with acidic residues on the channel. We also observed escapes of sodium

ions initially located in the selectivity filter in both KIIIA - hNav1.7 and KIIIA - hNav1.2 which

agrees with functional data showing that KIIIA incompletely blocks Nav channels. Interestingly,

despite having 150 mM of NaCl in the bulk solvent, we did not observe re-entering events of

sodium ions in the selectivity filter during the 3 independent 1.5 μs MD simulations. This possibly

can be explained by the relatively high percentage (> 94%) of KIIIA block observed in both

hNav1.7 and hNav1.2, which implied such re-binding events are rare and may not be observed in

our conventional 1.5 μs MD simulation trajectories. Our results agree with the functional data

showing that KIIIA is a highly efficient but incomplete pore blocker of Nav channels. Study of the

full binding and blocking mechanism of KIIIA on Nav channels is beyond the scope of this study

and will require much longer simulation times or enhanced sampling techniques, and a structure

of KIIIA bound to an open and conductive state of Nav channel, which is not currently available.

Our MD simulations results reflect dynamics of the binding configuration captured in our KIIIA -

hNav1.7 model and the KIIIA - hNav1.2 structure to provide a more comprehensive insights into

KIIIA – Nav channel interactions that extend beyond interpretation from the static structures.

We used an integrative Rosetta computational modeling, functional characterization, and MD

simulations approach to study molecular determinants of peptide toxin – Nav channel interactions.

Establishing successful predictions with computational modeling is a critical step towards

computational design of selective and potent peptide-based therapeutics. Our approach can be

potentially expanded to rational design of novel peptides to target the extracellular pore vestibule

region of Nav channels. Despite the high sequence conservation in the pore region of Nav channels,

our work shows that specific sequence differences between Nav channels in the extracellular loop

regions and the P2-helices of the pore can have important functional consequences on toxin –

channel interaction. Rosetta protein design (Kuhlman et al., 2003;Cao et al., 2020;Leman et al.,

2020) and optimization (Silva et al., 2019;Linsky et al., 2020) informed by these structural insights

could potentially lead to development of high-affinity and specificity peptide inhibitors of Nav

channels (Nguyen et al., 2022;Nguyen and Yarov-Yarovoy, 2022), forming a new class of

biologics to treat Nav channel related diseases.

Conclusions

We generated a structural model of the conotoxin KIIIA in complex with hNav1.7 using homology

modeling and docking simulations. Our model was validated with functional testing, using alanine-

scan mutagenesis of KIIIA and hNav1.7, double mutant cycle analysis of specific pairwise toxin

– channel interactions, supporting that acidic residues E919 and D923 on the P2-helix in DII of

Na$_V$1.7 significantly contribute to toxin – channel interaction, and that KIIIA forms multiple

interactions with the extracellular loops in DI-III. The published structure of the KIIIA - hNa$_V$1.2

complex further supports predictions observed in our model. Unbiased MD simulations of KIIIA

- hNa$_V$1.7 and KIIIA - hNa$_V$1.2 complexes suggest a potential important role of I1399 on the P2

helix in DIII of hNa$_V$1.7 that may underlie the structural basis of KIIIA block of hNa$_V$1.7

conductance. Overall, our results further characterize the molecular determinants of the KIIIA

interaction with human Nav channels and can be potentially useful for rational design of increases

in the potency or relative selectivity towards Nav1.7. As Nav1.7 is a drug target for pain (Payandeh

and Hackos, 2018;Bennett et al., 2019;Dib-Hajj and Waxman, 2019), such optimization of KIIIA

could result in novel peptide-based therapeutics.

Acknowledgments

We would like to thank Drs. Heike Wulff, Jie Zheng, and Igor Vorobyov, and members of Yarov-

Yarovoy and Sack laboratories for helpful discussions. We thank Dr. Nieng Yan (Princeton

University) for independent comparison of our KIIIA – hNa$_V$1.7 model to coordinates of KIIIA –

hNa$_V$1.2 structure (Pan et al., 2019) prior to release in Protein Data Bank, and sharing the

coordinates of electric eel and human Na$_V$1.2 channel structures. We thank Dr. Christoph Lossin

(University of California, Davis) for providing the hNa$_V$1.7 cell line and WT-hNa$_V$1.7 channel

construct, as well as Dr. William Catterall (University of Washington) for the tsa201 cell line.

Anton 2 computer time was provided by the Pittsburgh Supercomputing Center (PSC) through

Grant R01GM116961 from the National Institutes of Health. The Anton 2 machine (Shaw et al.,

2014) at PSC was generously made available by D.E. Shaw Research. This research was supported

Materials and methods

Homology modeling of hNav1.7 based on EeNav1.4 structure

The cryo-EM structure of the Nav1.4-β1 complex from the electric eel (eeNav1.4) (PDB ID: 5XSY) (Yan et al., 2017) was used to generate the model of hNav1.7 channel using Rosetta structural modeling software (Song et al., 2013;Bender et al., 2016). Initially, we refined the published coordinates of eeNav1.4, without the β1 subunit by using the Rosetta cryo-EM refinement protocol (Wang et al., 2016) and picked the lowest scoring density-refitted eeNav1.4 model to use as a template. The comparative modeling protocol RosettaCM (Song et al., 2013) was then used in combination with the electron density of the eeNav1.4 to model the hNav1.7 structure. We generated 5,000 structural models of hNav1.7 and selected the top 500 lowest-scoring models for clustering analysis as described previously (Bonneau et al., 2002). Visual inspection of the top scoring clustered models was used to select the final model for the docking study.

Molecular docking of KIIIA to the hNav1.7 model

The solution NMR structure of KIIIA (PDB ID: 2LXG) (Khoo et al., 2012) was used as an ensemble to dock to the hNav1.7 model using Rosetta protein-protein docking approach (Fleishman et al., 2011;Bender et al., 2016). By default, Rosetta moves proteins apart at the beginning of the protein-protein docking procedure which led to placement of KIIIA above the extracellular pore loops and did not allow sampling of the KIIIA binding site within the selectivity filter region because the KIIIA was not able to pass the narrow passage created by the extracellular pore loops. To address this problem, we subsequently divided the docking protocol into two stages

(see details of Rosetta commands and scripts in Supplementary File 1). In stage 1, docking was

performed with the DI S5P1 and DIII S5P1 loops truncated, and full random translational and

rotational perturbation of KIIIA at both low and high-resolution phases. This stage generated

20,000 structural models of the docking complexes. We then selected the top 1,000 models based

on the total scores and filtered based on the Rosetta $\Delta\Delta G$ (an estimate of the binding energy of a

complex) to select the top 500 models. $\Delta\Delta G$ is computed by taking the difference of the energy of

the KIIIA – hNav1.7 complex and of the separated KIIIA and hNav1.7 structures. We clustered

these complexes using the Rosetta legacy clustering application. The center models of top 20

clusters then passed to stage 2 docking. In this stage, positions of KIIIA in the top 20 clusters were

used to create 20 different starting docking trajectories with the full structure of hNav1.7 model

including all the extracellular loop regions. The full translational and rotational perturbation used

in the previous stage was turn off. Instead, only limited local perturbation was allowed in both

centroid and full-atom refinement phases. Similar to stage 1, we generated 20,000 structural

docking models and filtered based on the Rosetta total score and $\Delta\Delta G$ to select the top 500 models,

which were again clustered to finalize the top 5 complexes for visual inspection. The selected

docking model presented here (see coordinates of our KIIIA – hNav1.7 model in Supplement File

– Model 1) is the only one in the top 5 clusters models that has KIIIA partially occluding the pore

and K7 near the selectivity filter in agreement with experimental data demonstrating the

contribution of K7 to binding affinity and percentage block (Zhang et al., 2007;McArthur et al.,

2011).

Molecular dynamics simulation of KIIIA - hNav1.7 and KIIIA - hNav1.2 complexes

The docking complex of KIIIA - hNav1.7 and the cryo-EM structure of hNav1.2 (PDB ID: 6J8E)

were used to setup systems for MD simulations. For the hNav1.2 structure, Rosetta density

refinement protocol was applied as described above for the hNav1.7. The missing region on DI

extracellular loop was modeled using Rosetta loop modeling. We placed one sodium ion in the

selectivity filter and one in the cavity of the channels as initial setup for both simulations.

CHARMM-GUI (Jo et al., 2008) was used to embed the KIIIA - hNav1.7 model and the KIIIA -

hNav1.2 structure (PDB ID: 6J8E) in a lipid bilayer of POPC with explicit TIP3P water molecules

at a concentration of 150 mM NaCl. CHARMM36 forcefield was used for proteins, lipids, ions,

and waters in both systems. Each system contains approximately of 164,000 atoms. Protonation

state is assigned at neutral pH. N-epsilon nitrogen of H12 on KIIIA is protonated instead of N-

delta nitrogen as suggested in both the Rosetta model of hNav1.7 – KIIIA and the hNav1.2 – KIIIA

structure. The C-terminal of KIIIA is amidated to be consistent with the KIIIA variant used in our

experiments.

Equilibrations were run on our local GPU cluster using NAMD version 2.12 (Jiang et al., 2011).

After 10,000 steps of steepest descent minimization, MD simulations started with a timestep of 1

fs with harmonic restraints initially applied to protein heavy atoms and some lipid tail dihedral

angles as suggested by CHARMM-GUI (Jo et al., 2008). These restraints were slowly released

over 2 ns. Harmonic restraints ($0.1\,\text{kcal/mol/Å}^2$) were then applied only to protein backbone atoms,

and the systems were equilibrated further for 20 ns with a timestep of 2 fs. All bonds to H atoms

were constrained using the SHAKE algorithm in order to use a 2 fs timestep. Simulations were

performed in NPT ensemble with semi-isotropic pressure coupling to maintain the correct area per

lipid, and constant temperature of 303.15 K. Particle Mesh Ewald (PME) method was used to

compute electrostatic interactions. Non-bonded pair lists were updated every 10 steps with a list

cutoff distance of 16 Å and a real space cutoff of 12 Å with energy switching starting at 10 Å.

Independent simulation systems were created by using different seed numbers in the equilibrations.

We used the Anton 2 software version 1.31.0 for production runs of each system on the Anton 2

supercomputer. We ran 3 independent simulations of 1.5 μs for our hNav1.7 – KIIIA model and 3

independent simulations of 1μs for the hNav1.2 – KIIIA structure. Simulations were performed

in the NPT ensemble at 303.15 K A with 2 fs timestep. Non-bonded long-range interactions

computed every 6 fs using the RESPA multiple time step algorithm. The multi-integrator algorithm

was used for temperature and semi-isotropic pressure coupling and the u-series algorithm was used

for long-range electrostatic interactions. A long-range Lennard-Jones (LJ) correction (beyond

cutoff) was not used as was suggested for CHARMM36 lipid force field.

Modeling of KIIIA - hNav1.7 complex using NavAb structure: We previously performed

homology modeling of human Nav channels based on bacterial Nav channel structure before any

eukaryotic Nav channel structures were published. We first generated a model of hNav1.4 pore

using x-ray structure of the bacterial Nav channel NavAb (PDB ID: 3RVY) as a template using

Rosetta homology modeling (Bender et al., 2016). We selected to first model Nav1.4 channel

because of availability of experimental data on conotoxin – Nav channel interactions for model

validation (Dudley et al., 2000;Choudhary et al., 2007). The extracellular loop regions in hNav1.4

pore model were truncated and the P2 loops were rebuilt *de novo* using the Rosetta homology

modeling (Bender et al., 2016). We used available experimental data for conotoxin GIIIA

(homolog of KIIIA) interaction with Na$_V$1.4 channel (Dudley et al., 2000;Choudhary et al., 2007)

to guide the docking of GIIIA to hNa$_V$1.4 model. Specifically, charged residues R13 and K16 on

GIIIA were biased to interact with acidic residues on the Na$_V$1.4 P2 helices during docking using

Rosetta bounded restraints (Bender et al., 2016). We then used the top GIIIA - hNa$_V$1.4 model that

agreed with experimental data (Dudley et al., 2000;Choudhary et al., 2007) to build a model of

GIIIA - hNa$_V$1.7 complex using Rosetta homology modeling (Bender et al., 2016). To create the

initial configuration for KIIIA docking, we superimposed KIIIA onto GIIIA based on GIIIA -

hNa$_V$1.7 complex model. In this final docking step, KIIIA was docked using only full-atom

docking perturbations following by a flexible backbone refinement using Rosetta FlexPepDock

(Raveh et al., 2010) and the best model was selected using Rosetta interface score. We did not

perform experimental characterization on Na$_V$Ab based KIIIA - hNa$_V$1.7 complex model because

the subsequently published structures of eukaryotic Na$_V$ channels have allowed us to perform

higher accuracy homology modeling of hNa$_V$1.7 based on eeNa$_V$1.4 structure (described above).

Cell culture, transfection, and preparation

Electrophysiology experiments were performed on transiently transfected tsa-201 cells (gift from

William Catterall) and a HEK 293T cell line stably expressing hNa$_V$1.7 (gift from Chris Lossin).

Cells were grown at 37°C, 5% CO_2 in DMEM with 4.5g/L D-glucose, L-glutamine, and 110 mg/L

Sodium Pyruvate (Gibco cat# 11995-065) with 10% FBS, and 100 units/mL

Penicillin/Streptomycin (Gibco cat# 15140-122). The stable cell line was raised in the same

conditions with 500 μg/mL G418 as a selection agent. Cells were grown to 70% confluency in

35mm dishes and passaged every 2-3 days for tsa-201 and 3-4 days for the stable-cell line. Cells

were washed with divalent-free DPBS (Gibco cat# 14190-144) and dissociated with 0.05%

Trypsin-EDTA (Gibco cat# 25300-054) and seeded to fresh dishes with pre-warmed media. tsa-

201 cells were transfected via Lipofectamine 2000 24-48 hours prior to experiments with 1 μg

pCMV6-SCN9A (gift from Dr. Christoph Lossin) and 0.5 μg pMaxGFP (Lonza) for identification

of transfected cells. Mutant constructs were purchased, and coding sequences verified by

Mutagenex. Prior to experiments, cells were washed with DPBS and dissociated in 1mL Versene

(Gibco cat# 15040-066) and scraped from the dishes and transferred to a 14mL conical tube with

3 mL DMEM. They were centrifuged at 1000 x g for 2 minutes and resuspended in a microfuge

tube in 1mL extracellular solution (described below) with 10 mM D-glucose and rotated at RT

until use.

Electrophysiology

Whole-cell voltage-clamp recordings were performed at RT (21-22°C) in an RC-24N recording

chamber fixed to a glass coverslip (Warner Instruments), mounted on a Zeiss Axiovert 35

microscope illuminated with a Zeiss HBO 100W AttoArc lamp and filter set for epifluorescent

detection of GFP expressing cells. Approximately 40 μL of cell suspension was added to the pre-

filled chamber and allowed to adhere to the glass bottomed chamber for 2-10 minutes. Fresh

external solution was perfused through the chamber prior to patching. Borosilicate pipettes (1.5

mm OD, 0.86 mm ID, Sutter instruments cat # BF150-86-7.5HP) were pulled, fire-polished, coated

with Sylgard. Tip resistances were 1-2 MΩ, when filled with the internal recording solution. GFP

expressing cells were patched and signals were amplified with an Axon Axopatch 200-B

(Molecular Devices) and acquired with an Instrutech LIH 8+8 ADC board (HEKA). GΩ seals

were obtained, and pipette capacitance was corrected for prior to break-in achieved by suction.

Access resistance (R_s) was typically 1-4 MΩ. 60%-80% R_s compensation (10 μs lag) and

prediction was used to reduce voltage error to less than 10 mV as determined from the product of

the peak current and R_s with compensation. P/5 leak subtraction protocol was used during

recording. Signals were pre-filtered with a low-pass Bessel filter at 5 or 10 kHz before digitizing

at 20 kHz and recorded with Patchmaster (HEKA, version 2x90.2) on a Windows 7 PC. The

solutions were as follows in mM: External 3.5 KCl, 155 NaCl, 10 HEPES, 1 $MgCl_2$, 1.5 $CaCl_2$

adjusted to pH 7.4 with NaOH, and 315 mOsm; Internal: 35 NaCl, 70 CsCl, 50 CsF, 1 EGTA, 10

HEPES adjusted to pH 7.4 with CsOH at 310 mOsm. After break-in, cells were held at -120 mV

and tested for stable Na^+ current with depolarizing 35 ms voltage steps to -10 mV from -120 mV

collected every 5 s for up to 5 minutes to allow for a stable level of current prior to vehicle addition.

Once stable current levels were achieved, 150 µL of vehicle was manually added to the bath with

displaced solution removed via an overflow vacuum line. After approximately 5 minutes, whole

cell parameters were checked, and toxin (described below) was added by the same method as

vehicle. Once apparent block plateaued, whole cell parameters were checked and adjusted as

necessary, and pulsing resumed. To measure dissociation, gravity-fed perfusion with fresh external

solution was started at a rate 1-2 mL/min during recording. Cells with stable leak and R_s allowing

fitting to a single-exponential function (see below) throughout the experiment were included for

analysis.

Toxin preparation

Lyophilized WT-KIIIA was purchased (Alomone labs, Jerusalem, IS), reconstituted in water and

stored as 100 µM stock aliquots at -80°C prior to use. Toxin variants were produced by solid state

synthesis as described previously (Zhang et al., 2007) and stored as stock aliquots at -80°C prior

to use. Stock concentrations were checked by 280nm absorbance on a Nanodrop 2000

spectrophotometer (ThermoFisher) with extinction coefficients determined by the ExPASy

ProtParam online tool (Gasteiger et al., 2005). Stock aliquots of toxin were diluted in equal

volumes of 2x External solution with 0.2% BSA for working solutions of toxin in vehicle of 1x

External solution with 0.1% BSA and further diluted in 1x vehicle to the working concentration.

Vehicle for controls were prepared in the same manner.

Modeling and simulation analysis

Structural modeling data were analyzed using Rosetta and rendered using UCSF Chimera

(Pettersen et al., 2004), VMD (Humphrey et al., 1996) was used to analyze MD simulation data.

All data were plotted in R using ggplot2 (Hadley, 2016).

Tunnel detection for KIIIA block (Figure 1C): We used CAVER (version 3.0) (Chovancova

et al., 2012) to detect tunnels passing by KIIIA. Coordinates of Lys 7 in KIIIA were used as a

searching starting point with probe_radius 0.9, shell_radius 5.0, shell_depth 4.0 and max_distance

10. Multiple tunnels were detected for the whole structures. We visually select only tunnels that

have maximum radii greater than 2 and neighboring KIIIA for presentation.

Fractional contacts (Figure 5): Fractional contact is defined as probability of finding two

residues, one on the KIIIA and one on the channel forming contacts over time course of simulation.

We considered two residues are in contact if any heavy atoms of one residue is within 4 Å of any

heavy atoms of the other residues. Only contacts that have probability greater than 0.25 are shown

for clarity.

Interface RMSD (Figure 5 – figure supplement 1): We used 10 Å as a cutoff for interface

calculation between KIIIA and the channels. The interface is comprised of the KIIIA itself and

channel residues that are within 10 Å of KIIIA heavy atoms, defined at the beginning of the

simulations. Backbone heavy atoms of the interface were used for RMSD calculation.

Electrophysiology analysis

Electrophysiology data were analyzed and plotted in IGOR 7 Pro (Wavemetrics). Geometric

means of kinetic parameters were determined using Excel (Microsoft) and plotted in IGOR 7 Pro.

Curve fitting was performed in IGOR Pro 7 as described previously (Dockendorff et al., 2018). To

determine time constants of toxin association and dissociation (τ_{on} and τ_{off}, respectively), peak

currents during depolarizing voltage steps were plotted by time, and data were fit with a single

exponential function:

[1] $I_{Na^+} = I_{Na^+_0} + Ae^{-t-t_0/\tau}$

The association rate k_{on} was determined by equation 2, or equation 3 (McArthur et al., 2011) was

used for KIIIA- variant H12A where the maximal block at saturating concentrations (F_{block}) was

already known and k_{off} could not be determined independently:

[2] $k_{on} = \dfrac{\frac{1}{\tau_{on}} - k_{off}}{[tox]}$,

[3] $k_{on} = \dfrac{\frac{F_{[tox]}}{F_{block}}}{\tau_{on}*[tox]}$

k_{off} was determined by equation 4:

[4] $k_{off} = \dfrac{1}{\tau_{off}}$

Affinity was determined kinetically as the dissociation constant K_d via equation 5:

[5] $K_d = \dfrac{k_{off}}{k_{on}}$

The slow dissociation of WT-KIIIA from WT-hNav1.7 made measurement of k_{off} difficult due to

limited recovery during the experiment, thus values shown here are estimates assuming eventual

full recovery of the maximal current before toxin association. The resulting affinity values are

consistent with previous reporting of kinetic determination of affinity for this channel (McArthur

et al., 2011). Maximal block and IC_{50} for WT-KIIIA x WT-hNav1.7 was determined from

concentration-response of peak residual current at equilibrium with equation 6. The Hill coefficient

h was assumed to be 1 in accordance with a single binding site:

[6] $F_{[Tox]} = \dfrac{F_{block}}{\left\{ 1 + \left(\dfrac{IC_{50}}{[Tox]} \right)^h \right\}}$

Maximum fractional block at saturating concentrations was determined from kinetic data and

observed block ($F_{[tox]}$) for other channel and toxin variants, except where noted, according to

equation 7 (McArthur et al., 2011):

[7] $F_{block} = F_{[tox]} \left(1 + \dfrac{K_d}{[tox]} \right)$

The low affinity of H12A hindered precise measurement of dissociation kinetics; both the rapid

rate of dissociation and the low degree of block limited the number of data points for fitting a

single exponential to the dissociation data. The dissociation rate is extrapolated from Fractional

block assuming maximal block at saturating concentration of 0.877, as reported previously

(McArthur et al., 2011). The E919Q x D11A condition was affected by the same difficulty, thus

kinetic values reported assumed similar levels of block to those observed during the E919Q x WT-

KIIIA condition (0.92, Table 3). The lack of effect of KIIIA-D11A on channel block suggests that

any additive effect of the E919Q x D11A double mutant condition would not reduce the level of

block seen from WT-KIIIA on Nav1.7-E919Q. Any errors in estimation of maximal block with

toxin variants or channel mutants did not affect the calculation $K_d = k_{off} / k_{on}$, and thus did not affect

the coupling coefficients and energies calculated for double-mutant cycle analysis which are

derived from $K_d = k_{off} / k_{on}$.

Coupling coefficients (Ω) were calculated from the dissociation constants of the four conditions

for each cycle according to equation 8 (Hidalgo and MacKinnon, 1995), where "K_dwm" would

represent the dissociation constant for WT-hNav1.7 x Toxin-variant condition:

[8] $$\Omega = \frac{K_dww * K_dmm}{K_dwm * K_dmw}$$

Descriptive statistics: Arithmetic means and standard error were calculated for F_{block}, while

logarithmically scaled kinetic parameters were summarized with geometric means and standard

deviations. Standard errors of kinetic parameters were obtained for the tables as the dividend of

the standard deviation and the square root of the sample size for each toxin-channel pair, as noted

in parentheses in each table. Errors for coupling coefficients and coupling energies were calculated

by linear propagation of error from fractional standard deviations of the reported K_d values for the

toxin – channel mutant pairs used to calculate the coupling coefficients.

    Figure Legends

    Figure 1. **Structural model of KIIIA - hNaᵥ1.7 features eccentric binding of toxin to the outer**

    pore. (**A**) Structure and sequence of KIIIA (PDB: 2LXG) (Khoo et al., 2012) show an alpha

    helical core stabilized by three disulfide bridges. (**B**) Extracellular view of our KIIIA – hNaV1.7

    complex homology model based on the EeNaᵥ1.4-β1 cryo-EM structure (Yan et al., 2017).

    Channel domains are depicted according to color keys, and KIIIA is shown in magenta ribbon and

    surface. KIIIA binds eccentrically to the outer pore between DII and DIII. (**C**) A side view of

    channel pore reveals an incomplete block of KIIIA with KIIIA bound (magenta) and cavity

    volume. (**D**) Rosetta alanine scan identified residues K7, W8, R10, H12, and R14 as significant

    contributors to binding energy. (**E**) Heatmap of Rosetta ΔΔG on KIIIA structure shows the

    importance of the helical region for binding. (**F**) Close-up views of key interactions at KIIIA –

    hNaᵥ1.7 interface.

    Figure 2. **Functional studies of toxin variants and channel mutations**. (**A**) Normalized peak I_{Na}

    from a whole cell voltage clamp experiment with 10 μM WT-KIIIA against WT-hNaᵥ1.7,

    resulting in incomplete block and (inset) raw current traces before toxin (black) and after toxin

    (blue). (**B**) Hill-fit (black) and 95% confidence interval (dashed blue) of concentration-response

    data for WT-KIIIA against hNaᵥ1.7 in HEK293 cells (IC_{50}=0.41±0.16 μM mean±SD, n=2-4 cells

    per concentration), from maximum block recorded during association experiments. Empty circles

    represent single cells. (**C**) Calculated Fractional block (see Materials and methods) for toxin

    variants and channel mutants (mean±SEM). † WT x H12A block data were reported previously

    (McArthur et al., 2011). (**D**) Kinetic data from electrophysiological measurements show general

    agreement with Rosetta predicted energies. Alanine variants of residues K7, W8, D11, and H12

showed significant reductions in affinity (K_d)(left), little change in association (k_{on})(middle), but

marked increases in toxin dissociation (k_{off})(right). Bars are geometric mean±SD from n=3-5 cells

per variant (reported in Table 1), and empty circles represent single cells. (**E**) Mutations to channel

residues demonstrate reductions in affinity of the WT-KIIIA from Y362C, E919Q, and D923A

(left), little change to toxin association (middle), and increases in dissociation (right), similar to

the effects of toxin variants. Bars are geometric mean±SD from n=3-5 cells per variant (reported

in table 2), and empty circles represent single cells.

Figure 3. **Double mutant cycle analysis supports key pairwise interactions between KIIIA**

and h Nav**1.7**. (**A**) K_d, (**B**) k_{on}, and (**C**) k_{off} from double-mutant experiments of thermodynamic

double-mutant cycles between H12A x D923A, K7A x E919Q, and D11A x E919Q. Bars are

geometric mean±SD, n=2-5 cells per condition (reported in table 3), and empty circles are

individual cells. (D) Coupling coefficients Ω±error calculated from linear propagation of SEM of

K_d values from single and double-mutation experiments reported in Table 3.

Figure 4. **Marked difference for KIIIA binding specificity among** Nav **channel isoforms**. (**A**)

Comparisons of key residue interactions on the KIIIA - hNav1.7 model and the KIIIA - hNav1.2

structure. Domains and residue labels are depicted according to color keys. (**B**) Sequence

alignment of the different Nav subtypes at the interaction site with KIIIA. Different regions are

labeled. Key interacting residues of KIIIA are labeled and colored in magenta at positions of

corresponding interactions in channel residues. Superscripts show sequence number of hNav1.7.

Figure 5. MD simulations of KIIIA - hNav1.7 and KIIIA - hNav1.2 complexes show

structural dynamics of KIIIA interaction with hNav1.7 (A and C) and hNav1.2 (B and D).

(A, B) Couplings of K7 with key acidic residues on the hNav P2 helices. Density projections of

K7 (Nitrogen atom) and the acidic residue (oxygen atoms) on P2-helix (labeled) on the XY plane

(upper panel). For clarity, densities of the acidic residues are shown as contour plots using kernel

density estimation. Representative snapshots showing interactions of K7 with the acidic residues

at high density regions (labeled) identified from the density projections (lower panel). (C, D)

Heatmaps showing fractional contacts between key residues on KIIIA and hNav channels during

the simulations.

Figure 1—figure supplement 1. **Rosetta models of h**Nav**1.7 – KIIIA complex. Domains are**

depicted according to color keys. (**A**) Extracellular view of the pore region of the Rosetta model

of the KIIIA - hNav1.7 complex based on bacterial NavAb structure (Payandeh et al., 2011). (**B**)

Extracellular view of the pore region of the KIIIA - hNav1.7 model based on eeNav1.4 structure

(Yan et al., 2017) in superposition with the cryo-EM structure of the KIIIA - hNav1.2 complex

(Pan et al., 2019).

Figure 2—figure supplement 1. **Representative data from functional studies of toxin variants**

and channel mutations. (**A**) Normalized peak $I_{Na}+$ from whole cell voltage clamp experiments

with WT-hNav1.7 in the presence of toxin variants as stated in each plot, exponential fits of

association and dissociation shown in blue. Raw current traces (inset) before toxin (black) and

after toxin addition (blue). (**B**) Normalized peak $I_{Na}+$ from whole cell voltage clamp experiments

with hNav1.7 mutants as labeled in the presence of WT-KIIIA as in panel A.

Figure 3—figure supplement 1. Representative data from double-mutant cycle analysis. (**A**)

Normalized peak $I_{Na}+$ from whole cell voltage clamp experiments with WT x WT, single, and

double mutations D923A and H12A as indicated by column and row labels. Exponential fits of

association and dissociation shown in blue. Raw current traces (inset) before toxin (black) and

after toxin addition (blue). (**B**) Normalized peak $I_{Na}+$ from whole cell voltage clamp experiments,

as in panel A for the two residue pairs E919 x K7 and E919 x D11.

Figure 4—figure supplement 1. **Differences in interactions of KIIIA residues D11 (left panel)**

and R10 (right panel) between the KIIIA - h Nav**1.7 model and the KIIIA - h**Nav**1.2 structure**.

Both alternative sidechain rotamers of KIIIA R10 residue identified in the KIIIA - hNaV1.2

structure are shown. Domains and labels are depicted according to color keys.

Figure 5—figure supplement 1. MD simulation of KIIIA - h Nav**1.7 model and KIIIA –**

hNav**1.2 structure.** (**A**) Interfacial RMSD of the KIIIA – hNav1.7 and KIIIA – hNav1.2

complexes in different independent simulations. (**B**) Couplings of R10 with key acidic residues on

the P2 helices of hNav1.7 (upper panel) and hNav1.2 (lower panel) are depicted as density

projections of R10 and the acidic residue on P2-helix (labeled) on the XY plane. For clarity,

densities of the acidic residues are shown as contour plots using kernel density estimation.

Figure 5—figure supplement 2. **MD simulation of KIIIA - h**Nav**1.7 model**. (**A**) Time series of

representative contacts of K7 and R10 with acidic residues on P2 helix of hNav1.7. Labels show

residue numbers and their associated atom names (in parenthesis). (**B**) A snapshot of the last frame

of the 1μs simulation. Domains are depicted according to color keys and channel residues that

have high fractional contacts in Figure 5A are shown in stick representation and labeled.

Figure 5—figure supplement 3. **MD simulation of KIIIA - h**Nav**1.2 model**. (**A**) Time series of

representative contacts of K7 and R10 with acidic residues on P2 helix of hNav1.7. Labels show

residue numbers and their associated atom names (in parenthesis). (**B**) A snapshot of the last frame

of the 1μs simulation. Domains are depicted according to color keys and channel residues that

have high fractional contacts in Figure 5B are shown in stick representation and labeled.

References

Ahern, C.A., Payandeh, J., Bosmans, F., and Chanda, B. (2016). The hitchhiker's guide to the

voltage-gated sodium channel galaxy. *J Gen Physiol* 147**,** 1-24.

Bender, B.J., Cisneros, A., 3rd, Duran, A.M., Finn, J.A., Fu, D., Lokits, A.D., Mueller, B.K.,

Sangha, A.K., Sauer, M.F., Sevy, A.M., Sliwoski, G., Sheehan, J.H., Dimaio, F., Meiler,

J., and Moretti, R. (2016). Protocols for Molecular Modeling with Rosetta3 and

RosettaScripts. *Biochemistry* 55**,** 4748-4763.

Bennett, D.L., Clark, A.J., Huang, J., Waxman, S.G., and Dib-Hajj, S.D. (2019). The Role of

Voltage-Gated Sodium Channels in Pain Signaling. *Physiol Rev* 99**,** 1079-1151.

Bonneau, R., Strauss, C.E., Rohl, C.A., Chivian, D., Bradley, P., Malmstrom, L., Robertson, T.,

and Baker, D. (2002). De novo prediction of three-dimensional structures for major

protein families. *J Mol Biol* 322**,** 65-78.

Cao, L., Goreshnik, I., Coventry, B., Case, J.B., Miller, L., Kozodoy, L., Chen, R.E., Carter, L.,

Walls, A.C., Park, Y.J., Strauch, E.M., Stewart, L., Diamond, M.S., Veesler, D., and

Baker, D. (2020). De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.

Science 370**,** 426-431.

Catterall, W.A. (2014). Structure and function of voltage-gated sodium channels at atomic

resolution. *Exp Physiol* 99**,** 35-51.

Catterall, W.A., Goldin, A.L., and Waxman, S.G. (2005). International Union of Pharmacology.

XLVII. Nomenclature and structure-function relationships of voltage-gated sodium

channels. *Pharmacol Rev* 57**,** 397-409.

Choudhary, G., Aliste, M.P., Tieleman, D.P., French, R.J., and Dudley, S.C., Jr. (2007). Docking

of mu-conotoxin GIIIA in the sodium channel outer vestibule. *Channels (Austin)* 1**,** 344-

352.

Chovancova, E., Pavelka, A., Benes, P., Strnad, O., Brezovsky, J., Kozlikova, B., Gora, A.,

Sustr, V., Klvana, M., Medek, P., Biedermannova, L., Sochor, J., and Damborsky, J.

(2012). CAVER 3.0: a tool for the analysis of transport pathways in dynamic protein

structures. *PLoS Comput Biol* 8**,** e1002708.

Dib-Hajj, S.D., and Waxman, S.G. (2019). Sodium Channels in Human Pain Disorders: Genetics

and Pharmacogenomics. *Annu Rev Neurosci*.

Dib-Hajj, S.D., Yang, Y., Black, J.A., and Waxman, S.G. (2013). The Na(V)1.7 sodium channel:

from molecule to man. *Nat Rev Neurosci* 14**,** 49-62.

Dockendorff, C., Gandhi, D.M., Kimball, I.H., Eum, K.S., Rusinova, R., Ingolfsson, H.I.,

Kapoor, R., Peyear, T., Dodge, M.W., Martin, S.F., Aldrich, R.W., Andersen, O.S., and

Sack, J.T. (2018). Synthetic Analogues of the Snail Toxin 6-Bromo-2-

mercaptotryptamine Dimer (BrMT) Reveal That Lipid Bilayer Perturbation Does Not

Underlie Its Modulation of Voltage-Gated Potassium Channels. *Biochemistry* 57**,** 2733-

2743.

Dudley, S.C., Jr., Chang, N., Hall, J., Lipkind, G., Fozzard, H.A., and French, R.J. (2000). mu-

conotoxin GIIIA interactions with the voltage-gated Na(+) channel predict a clockwise

arrangement of the domains. *J Gen Physiol* 116**,** 679-690.

Fan, X., Huang, J., Jin, X., and Yan, N. (2023). Cryo-EM structure of human voltage-gated

sodium channel Na(v)1.6. *Proc Natl Acad Sci U S A* 120**,** e2220578120.

Fleishman, S.J., Leaver-Fay, A., Corn, J.E., Strauch, E.M., Khare, S.D., Koga, N., Ashworth, J.,

Murphy, P., Richter, F., Lemmon, G., Meiler, J., and Baker, D. (2011). RosettaScripts: a

scripting language interface to the Rosetta macromolecular modeling suite. *PloS one* 6**,**

e20161.

French, R.J., Yoshikami, D., Sheets, M.F., and Olivera, B.M. (2010). The tetrodotoxin receptor

896   of voltage-gated sodium channels--perspectives from interactions with micro-conotoxins.

897   *Mar Drugs* 8**,** 2153-2161.

898   Gasteiger, E., Hoogland, C., Gattiker, A., Duvaud, S., Wilkins, M.R., Appel, R.D., and Bairoch,

899   A. (2005). "Protein Identification and Analysis Tools on the ExPASy Server;," in *The*

900   *Proteomics Protocols Handbook,* ed. J.M. Walker. Humana Press), 571-607.

901   Gilchrist, J., Olivera, B.M., and Bosmans, F. (2014). Animal toxins influence voltage-gated

902   sodium channel function. *Handb Exp Pharmacol* 221**,** 203-229.

903   Gray, J.J., Moughon, S., Wang, C., Schueler-Furman, O., Kuhlman, B., Rohl, C.A., and Baker,

904   D. (2003). Protein-protein docking with simultaneous optimization of rigid-body

905   displacement and side-chain conformations. *J Mol Biol* 331**,** 281-299.

906   Hadley, W. (2016). *Ggplot2.* New York, NY: Springer Science+Business Media, LLC.

907   Hidalgo, P., and Mackinnon, R. (1995). Revealing the architecture of a K+ channel pore through

908   mutant cycles with a peptide inhibitor. *Science* 268**,** 307-310.

909   Hille, B. (2001). *Ion Channels of Excitable Membranes.* Sinauer Associates, Sunderland, MA).

910   Huang, G., Wu, Q., Li, Z., Jin, X., Huang, X., Wu, T., Pan, X., and Yan, N. (2022a). Unwinding

911   and spiral sliding of S4 and domain rotation of VSD during the electromechanical

912   coupling in Na(v)1.7. *Proc Natl Acad Sci U S A* 119**,** e2209164119.

913   Huang, X., Jin, X., Huang, G., Huang, J., Wu, T., Li, Z., Chen, J., Kong, F., Pan, X., and Yan, N.

914   (2022b). Structural basis for high-voltage activation and subtype-specific inhibition of

915   human Na(v)1.8. *Proc Natl Acad Sci U S A* 119**,** e2208211119.

916   Humphrey, W., Dalke, A., and Schulten, K. (1996). VMD: visual molecular dynamics. *J Mol*

917   *Graph* 14**,** 33-38, 27-38.

Jiang, D., Banh, R., Gamal El-Din, T.M., Tonggu, L., Lenaeus, M.J., Pomes, R., Zheng, N., and

Catterall, W.A. (2021). Open-state structure and pore gating mechanism of the cardiac

sodium channel. *Cell* 184**,** 5151-5162 e5111.

Jiang, D., Shi, H., Tonggu, L., Gamal El-Din, T.M., Lenaeus, M.J., Zhao, Y., Yoshioka, C.,

Zheng, N., and Catterall, W.A. (2020). Structure of the Cardiac Sodium Channel. *Cell*

180**,** 122-134 e110.

Jiang, W., Hardy, D.J., Phillips, J.C., Mackerell, A.D., Jr., Schulten, K., and Roux, B. (2011).

High-performance scalable molecular dynamics simulations of a polarizable force field

based on classical Drude oscillators in NAMD. *J Phys Chem Lett* 2**,** 87-92.

Jo, S., Kim, T., Iyer, V.G., and Im, W. (2008). CHARMM-GUI: a web-based graphical user

interface for CHARMM. *J Comput Chem* 29**,** 1859-1865.

Khoo, K.K., Gupta, K., Green, B.R., Zhang, M.M., Watkins, M., Olivera, B.M., Balaram, P.,

Yoshikami, D., Bulaj, G., and Norton, R.S. (2012). Distinct disulfide isomers of mu-

conotoxins KIIIA and KIIIB block voltage-gated sodium channels. *Biochemistry* 51**,**

9826-9835.

Korkosh, V.S., Zhorov, B.S., and Tikhonov, D.B. (2014). Folding similarity of the outer pore

region in prokaryotic and eukaryotic sodium channels revealed by docking of conotoxins

GIIIA, PIIIA, and KIIIA in a NavAb-based model of Nav1.4. *J Gen Physiol* 144**,** 231-

244.

Ku, H.H. (1966). Notes on the use of propagation of error formulas. *Journal of Research of the*

National Bureau of Standards. Section C: Engineering and Instrumentation 70C**,** 263-

272.

Kubota, T., Durek, T., Dang, B., Finol-Urdaneta, R.K., Craik, D.J., Kent, S.B., French, R.J.,

Bezanilla, F., and Correa, A.M. (2017). Mapping of voltage sensor positions in resting

and inactivated mammalian sodium channels by LRET. *Proc Natl Acad Sci U S A* 114**,**

E1857-E1865.

Kuhlman, B., Dantas, G., Ireton, G.C., Varani, G., Stoddard, B.L., and Baker, D. (2003). Design

of a novel globular protein fold with atomic-level accuracy. *Science* 302**,** 1364-1368.

Leman, J.K., Weitzner, B.D., Lewis, S.M., Adolf-Bryfogle, J., Alam, N., Alford, R.F.,

Aprahamian, M., Baker, D., Barlow, K.A., Barth, P., Basanta, B., Bender, B.J.,

Blacklock, K., Bonet, J., Boyken, S.E., Bradley, P., Bystroff, C., Conway, P., Cooper, S.,

Correia, B.E., Coventry, B., Das, R., De Jong, R.M., Dimaio, F., Dsilva, L., Dunbrack,

R., Ford, A.S., Frenz, B., Fu, D.Y., Geniesse, C., Goldschmidt, L., Gowthaman, R., Gray,

J.J., Gront, D., Guffy, S., Horowitz, S., Huang, P.S., Huber, T., Jacobs, T.M., Jeliazkov,

J.R., Johnson, D.K., Kappel, K., Karanicolas, J., Khakzad, H., Khar, K.R., Khare, S.D.,

Khatib, F., Khramushin, A., King, I.C., Kleffner, R., Koepnick, B., Kortemme, T.,

Kuenze, G., Kuhlman, B., Kuroda, D., Labonte, J.W., Lai, J.K., Lapidoth, G., Leaver-

Fay, A., Lindert, S., Linsky, T., London, N., Lubin, J.H., Lyskov, S., Maguire, J.,

Malmstrom, L., Marcos, E., Marcu, O., Marze, N.A., Meiler, J., Moretti, R., Mulligan,

V.K., Nerli, S., Norn, C., O'conchuir, S., Ollikainen, N., Ovchinnikov, S., Pacella, M.S.,

Pan, X., Park, H., Pavlovicz, R.E., Pethe, M., Pierce, B.G., Pilla, K.B., Raveh, B.,

Renfrew, P.D., Burman, S.S.R., Rubenstein, A., Sauer, M.F., Scheck, A., Schief, W.,

Schueler-Furman, O., Sedan, Y., Sevy, A.M., Sgourakis, N.G., Shi, L., Siegel, J.B., Silva,

D.A., Smith, S., Song, Y., et al. (2020). Macromolecular modeling and design in Rosetta:

recent methods and frameworks. *Nat Methods* 17**,** 665-680.

Li, X., Xu, F., Xu, H., Zhang, S., Gao, Y., Zhang, H., Dong, Y., Zheng, Y., Yang, B., Sun, J.,

Zhang, X.C., Zhao, Y., and Jiang, D. (2022). Structural basis for modulation of human

Na(V)1.3 by clinical drug and selective antagonist. *Nat Commun* 13**,** 1286.

Linsky, T.W., Vergara, R., Codina, N., Nelson, J.W., Walker, M.J., Su, W., Barnes, C.O.,

Hsiang, T.Y., Esser-Nobis, K., Yu, K., Reneer, Z.B., Hou, Y.J., Priya, T., Mitsumoto, M.,

Pong, A., Lau, U.Y., Mason, M.L., Chen, J., Chen, A., Berrocal, T., Peng, H., Clairmont,

N.S., Castellanos, J., Lin, Y.R., Josephson-Day, A., Baric, R.S., Fuller, D.H., Walkey,

C.D., Ross, T.M., Swanson, R., Bjorkman, P.J., Gale, M., Jr., Blancas-Mejia, L.M., Yen,

H.L., and Silva, D.A. (2020). De novo design of potent and resilient hACE2 decoys to

neutralize SARS-CoV-2. *Science* 370**,** 1208-1214.

Mcarthur, J.R., Singh, G., Mcmaster, D., Winkfein, R., Tieleman, D.P., and French, R.J. (2011).

Interactions of key charged residues contributing to selective block of neuronal sodium

channels by mu-conotoxin KIIIA. *Mol Pharmacol* 80**,** 573-584.

Mulcahy, J.V., Pajouhesh, H., Beckley, J.T., Delwig, A., Du Bois, J., and Hunter, J.C. (2019).

Challenges and Opportunities for Therapeutics Targeting the Voltage-Gated Sodium

Channel Isoform NaV1.7. *J Med Chem* 62**,** 8695-8710.

Nguyen, P.T., Demarco, K.R., Vorobyov, I., Clancy, C.E., and Yarov-Yarovoy, V. (2019).

Structural basis for antiarrhythmic drug interactions with the human cardiac sodium

channel. *Proc Natl Acad Sci U S A* 116**,** 2945-2954.

Nguyen, P.T., Nguyen, H.M., Wagner, K.M., Stewart, R.G., Singh, V., Thapa, P., Chen, Y.J.,

Lillya, M.W., Ton, A.T., Kondo, R., Ghetti, A., Pennington, M.W., Hammock, B.,

Griffith, T.N., Sack, J.T., Wulff, H., and Yarov-Yarovoy, V. (2022). Computational

design of peptides to target Na(V)1.7 channel with high potency and selectivity for the

treatment of pain. *Elife* 11.

Nguyen, P.T., and Yarov-Yarovoy, V. (2022). Towards Structure-Guided Development of Pain

Therapeutics Targeting Voltage-Gated Sodium Channels. *Front Pharmacol* 13**,** 842032.

Pajouhesh, H., Beckley, J.T., Delwig, A., Hajare, H.S., Luu, G., Monteleone, D., Zhou, X.,

Ligutti, J., Amagasu, S., Moyer, B.D., Yeomans, D.C., Du Bois, J., and Mulcahy, J.V.

(2020). Discovery of a selective, state-independent inhibitor of NaV1.7 by modification

of guanidinium toxins. *Sci Rep* 10**,** 14791.

Pan, X., Li, Z., Huang, X., Huang, G., Gao, S., Shen, H., Liu, L., Lei, J., and Yan, N. (2019).

Molecular basis for pore blockade of human Na(+) channel Nav1.2 by the mu-conotoxin

KIIIA. *Science* 363**,** 1309-1313.

Pan, X., Li, Z., Jin, X., Zhao, Y., Huang, G., Huang, X., Shen, Z., Cao, Y., Dong, M., Lei, J., and

Yan, N. (2021). Comparative structural analysis of human Na(v)1.1 and Na(v)1.5 reveals

mutational hotspots for sodium channelopathies. *Proc Natl Acad Sci U S A* 118.

Pan, X., Li, Z., Zhou, Q., Shen, H., Wu, K., Huang, X., Chen, J., Zhang, J., Zhu, X., Lei, J.,

Xiong, W., Gong, H., Xiao, B., and Yan, N. (2018). Structure of the human voltage-gated

sodium channel Nav1.4 in complex with beta1. *Science*.

Payandeh, J., and Hackos, D.H. (2018). Selective Ligands and Drug Discovery Targeting the

Voltage-Gated Sodium Channel Nav1.7. *Handb Exp Pharmacol* 246**,** 271-306.

Payandeh, J., Scheuer, T., Zheng, N., and Catterall, W.A. (2011). The crystal structure of a

voltage-gated sodium channel. *Nature* 475**,** 353-358.

1006 Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C., and

1007   Ferrin, T.E. (2004). UCSF Chimera--a visualization system for exploratory research and

1008   analysis. *J Comput Chem* 25**,** 1605-1612.

1009 Ragsdale, D.S., Mcphee, J.C., Scheuer, T., and Catterall, W.A. (1994). Molecular determinants

1010   of state-dependent block of Na+ channels by local anesthetics. *Science* 265**,** 1724-1728.

1011 Ranganathan, R., Lewis, J.H., and Mackinnon, R. (1996). Spatial localization of the K+ channel

1012   selectivity filter by mutant cycle-based structure analysis. *Neuron* 16**,** 131-139.

1013 Raveh, B., London, N., and Schueler-Furman, O. (2010). Sub-angstrom modeling of complexes

1014   between flexible peptides and globular proteins. *Proteins* 78**,** 2029-2040.

1015 Schreiber, G., and Fersht, A.R. (1995). Energetics of protein-protein interactions: Analysis ofthe

1016   Barnase-Barstar interface by single mutations and double mutant cycles. *Journal of*

1017   *Molecular Biology* 248**,** 478-486.

1018 Shaw, D.E., Grossman, J.P., Bank, J.A., Batson, B., Butts, J.A., Chao, J.C., Deneroff, M.M.,

1019   Dror, R.O., Even, A., Fenton, C.H., Forte, A., Gagliardo, J., Gill, G., Greskamp, B., Ho,

1020   C.R., Ierardi, D.J., Iserovich, L., Kuskin, J.S., Larson, R.H., Layman, T., Lee, L.S., Lerer,

1021   A.K., Li, C., Killebrew, D., Mackenzie, K.M., Mok, S.Y.H., Moraes, M.A., Mueller, R.,

1022   Nociolo, L.J., Peticolas, J.L., Quan, T., Ramot, D., Salmon, J.K., Scarpazza, D.P., Ben

1023   Schafer, U., Siddique, N., Snyder, C.W., Spengler, J., Tang, P.T.P., Theobald, M., Toma,

1024   H., Towles, B., Vitale, B., Wang, S.C., and Young, C. (2014). Anton 2: Raising the bar

1025   for performance and programmability in a special-purpose molecular dynamics

1026   supercomputer. *Sc14: International Conference for High Performance Computing,*

1027   *Networking, Storage and Analysis***,** 41-53.

1028   Shen, H., Li, Z., Jiang, Y., Pan, X., Wu, J., Cristofori-Armstrong, B., Smith, J.J., Chin, Y.K.Y.,

1029   Lei, J., Zhou, Q., King, G.F., and Yan, N. (2018). Structural basis for the modulation of

1030   voltage-gated sodium channels by animal toxins. *Science*.

1031   Shen, H., Liu, D., Wu, K., Lei, J., and Yan, N. (2019). Structures of human Nav1.7 channel in

1032   complex with auxiliary subunits and animal toxins. *Science* 363**,** 1303-1308.

1033   Silva, D.A., Yu, S., Ulge, U.Y., Spangler, J.B., Jude, K.M., Labao-Almeida, C., Ali, L.R.,

1034   Quijano-Rubio, A., Ruterbusch, M., Leung, I., Biary, T., Crowley, S.J., Marcos, E.,

1035   Walkey, C.D., Weitzner, B.D., Pardo-Avila, F., Castellanos, J., Carter, L., Stewart, L.,

1036   Riddell, S.R., Pepper, M., Bernardes, G.J.L., Dougan, M., Garcia, K.C., and Baker, D.

1037   (2019). De novo design of potent and selective mimics of IL-2 and IL-15. *Nature* 565**,**

1038   186-191.

1039   Siteone Therapeutics, I. (2021). *A Phase 1, Randomized, Double-Blind, Placebo-Controlled*

1040   *Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics*

1041   *of ST-2427 IV Infusion in Healthy Subjects*. USA patent application.

1042   Song, Y., Dimaio, F., Wang, R.Y., Kim, D., Miles, C., Brunette, T., Thompson, J., and Baker, D.

1043   (2013). High-resolution comparative modeling with RosettaCM. *Structure* 21**,** 1735-

1044   1742.

1045   Wang, C., Bradley, P., and Baker, D. (2007). Protein-protein docking with backbone flexibility.

1046   *J Mol Biol* 373**,** 503-519.

1047   Wang, R.Y., Song, Y., Barad, B.A., Cheng, Y., Fraser, J.S., and Dimaio, F. (2016). Automated

1048   structure refinement of macromolecular assemblies from cryo-EM maps using Rosetta.

1049   *Elife* 5.

Wilson, M.J., Yoshikami, D., Azam, L., Gajewiak, J., Olivera, B.M., Bulaj, G., and Zhang, M.M.

(2011). mu-Conotoxins that differentially block sodium channels NaV1.1 through 1.8

identify those responsible for action potentials in sciatic nerve. *Proc Natl Acad Sci U S A*

108**, 10302-10307.

Yan, Z., Zhou, Q., Wang, L., Wu, J., Zhao, Y., Huang, G., Peng, W., Shen, H., Lei, J., and Yan,

N. (2017). Structure of the Nav1.4-beta1 Complex from Electric Eel. *Cell* 170**, 470-482

e411.

Yarov-Yarovoy, V., Brown, J., Sharp, E.M., Clare, J.J., Scheuer, T., and Catterall, W.A. (2001).

Molecular determinants of voltage-dependent gating and binding of pore-blocking drugs

in transmembrane segment IIIS6 of the Na(+) channel alpha subunit. *J Biol Chem* 276**,

20-27.

Yarov-Yarovoy, V., Mcphee, J.C., Idsvoog, D., Pate, C., Scheuer, T., and Catterall, W.A. (2002).

Role of amino acid residues in transmembrane segments IS6 and IIS6 of the Na+ channel

alpha subunit in voltage-dependent gating and drug block. *J Biol Chem* 277**, 35393-

35401.

Zhang, M.M., Green, B.R., Catlin, P., Fiedler, B., Azam, L., Chadwick, A., Terlau, H., Mcarthur,

J.R., French, R.J., Gulyas, J., Rivier, J.E., Smith, B.J., Norton, R.S., Olivera, B.M.,

Yoshikami, D., and Bulaj, G. (2007). Structure/function characterization of micro-

conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal

sodium channels. *J Biol Chem* 282**, 30699-30706.

Zhang, M.M., Mcarthur, J.R., Azam, L., Bulaj, G., Olivera, B.M., French, R.J., and Yoshikami,

D. (2009). Synergistic and antagonistic interactions between tetrodotoxin and mu-

conotoxin in blocking voltage-gated sodium channels. *Channels (Austin)* 3**, 32-38.

1073

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 1—figure supplement 1

| DI | DII | DIII | DIV | KIIIA | hNav1.2 | KIIIA(hNav1.2) |

A

NavAb-based model

B

EeNav1.4-based model

Figure 2—figure supplement 1

Figure 4—figure supplement 1

Figure 5— figure supplement 1

A

B

Couplings of R10 with key acidic residues on hNav1.7 P2 helices

Couplings of R10 with key acidic residues on hNav1.2 P2 helices

Figure 5—figure supplement 2

A

Representative atomic contacts of K7 and R10 with acidic residues on P2 helix of hNav1.7

B

Figure 5— figure supplement 3

A

Representative atomic contacts of K7 and R10 with acidic residues on P2 helix of hNav1.2